masld glp 1 Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with Incretin-based therapies in MASLD/MASH: from

While the total drug exposure remained comparable across all three sites, the thigh produced fewer acute gastrointestinal side effects in the study participants

This data reached mainstream outlets, fuelling public interest and normalising these drugs as legitimate medical interventions

An HHS official called her a radical leftist in national media

Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes

The most frequent adverse events associated with resmetirom were diarrhea and nausea

Determine whether high numbers of members are dropping out of GLP 1 treatments before seeing therapeutic benefits